Plasma concentrations of soluble cytokine receptors in euthymic bipolar patients with and without subsyndromal symptoms

BMC Psychiatry

Jim van Os³  E Timucin Oral⁴  Gunnur Deniz¹  Sema Bilgic Gazioglu¹  Esin Aktas Cetin¹  Sinan Guloksuz⁵  Turan Cetin² 

[1] Department of Immunology, Institute of Experimental Medicine (DETAE), Istanbul University, Istanbul, Turkey;Research, Treatment and Training Center for Alcohol and Substance Dependence (AMATEM), Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey;King’s College London, King’s Health Partners, Department of Psychosis Studies, Institute of Psychiatry, London, United Kingdom;Department of Psychology, Faculty of Arts and Sciences, Istanbul Commerce University, Istanbul, Turkey;Department of Psychiatry and Psychology, Maastricht University Medical Centre, EURON, Maastricht, The Netherlands

关键词: Biomarker;    Staging;    Subsyndromal;    Euthymic;    Tumor necrosis factor;    Inflammation;    Interleukin;    Cytokine;    Bipolar disorder;   

Others  :  1124273
DOI  :  10.1186/1471-244X-12-158

 received in 2012-05-17, accepted in 2012-09-21,  发布年份 2012

【 摘 要 】

Background

Current evidence suggests that high concentrations of pro-inflammatory markers are associated with bipolar disorder characterized by severe impairment during inter-episodic periods, reduced treatment response and persistent subsyndromal symptoms. We tested whether persistent subsyndromal symptoms in euthymic bipolar patients were associated with markers of an ongoing chronic pro-inflammatory process.

Methods

Forty-five euthymic bipolar patients (22 with subsyndromal symptoms (BD+) and 23 without subsyndromal symptoms (BD-) and 23 well controls (WC) were recruited for assessment of soluble tumor necrosis factor receptor-1 (sTNF-R1), soluble interleukin-6 receptor (sIL-6R) and soluble interleukin-2 receptor (sIL-2R) concentrations. Soluble cytokine receptor concentrations were assessed using enzyme-linked immunosorbent assay.

Results

In comparison to WC, sTNF-R1 concentration was higher in both BD- and BD+ (age and sex adjusted standardized β, respectively: β = 0.34, p = 0.012 and β = 0.41, p = 0.003). Similarly, compared to WC, sIL-6R concentration was higher in both BD- and BD+ (age and sex adjusted standardized β, respectively: β = 0.44, p = 0.001 and β = 0.37, p = 0.008). There was no difference between BD- and BD+ in the concentration of either sTNF-R1 or sIL-6R; plasma concentration of sIL-2R was not analyzed as 75% percent of the samples were non-detectable.

Conclusions

Although bipolar patients present with a pro-inflammatory shift compared to well controls, subsyndromal symptoms are not associated with additive increasing effects. Longitudinal studies with larger samples are required to clarify the relationship between illness course and inflammatory markers in bipolar disorder.

【 授权许可】

   
2012 Cetin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, Solomon DA, Leon AC, Keller MB: A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003, 60(3):261-269.
• [2]Marangell LB: The importance of subsyndromal symptoms in bipolar disorder. J Clin Psychiatry 2004, 65(Suppl 10):24-27.
• [3]Marangell LB, Dennehy EB, Miyahara S, Wisniewski SR, Bauer MS, Rapaport MH, Allen MH: The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD. J Affect Disord 2009, 114(1–3):58-67.
• [4]Montoya A, Tohen M, Vieta E, Casillas M, Chacon F, Polavieja P, Gilaberte I: Functioning and symptomatic outcomes in patients with bipolar I disorder in syndromal remission: a 1-year, prospective, observational cohort study. J Affect Disord 2010, 127(1–3):50-57.
• [5]Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS: Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009, 70(8):1078-1090.
• [6]Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO, McIntyre RS: The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology 2009, 30(4):497-521.
• [7]Kronfol Z, Remick DG: Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000, 157(5):683-694.
• [8]Brietzke E, Stertz L, Fernandes BS, Kauer-Sant'anna M, Mascarenhas M, Escosteguy Vargas A, Chies JA, Kapczinski F: Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009, 116(3):214-217.
• [9]Guloksuz S, Cetin EA, Cetin T, Deniz G, Oral ET, Nutt DJ: Cytokine levels in euthymic bipolar patients. J Affect Disord 2010, 126(3):458-462.
• [10]Kunz M, Cereser KM, Goi PD, Fries GR, Teixeira AL, Fernandes BS, Belmonte-de-Abreu PS, Kauer-Sant'Anna M, Kapczinski F, Gama CS: Serum levels of IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance. Rev Bras Psiquiatr 2011, 33(3):268-274.
• [11]Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'Anna M, Klamt F, Moreira JC, de Bittencourt Pasquali MA, Fries GR, Quevedo J, et al.: Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res 2011, 45(2):156-161.
• [12]Guloksuz S, Altinbas K, Aktas Cetin E, Kenis G, Bilgic Gazioglu S, Deniz G, Oral ET, van Os J: Evidence for an association between tumor necrosis factor-alpha levels and lithium response. J Affect Disord 2012.
• [13]Kapczinski F, Dias VV, Kauer-Sant'Anna M, Brietzke E, Vazquez GH, Vieta E, Berk M: The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(8):1366-1371.
• [14]Post RM, Fleming J, Kapczinski F: Neurobiological correlates of illness progression in the recurrent affective disorders. J Psychiatr Res 2012, 46(5):561-573.
• [15]Munkholm K, Vinberg M, Vedel Kessing L: Cytokines in bipolar disorder: A systematic review and meta-analysis. J Affect Disord 2012.
• [16]Tirpan K, Ozerdem A, Tunca Z, Yazici O, Oral ET, Kurt E, Vahip S: A computerized registry program for bipolar illness in Turkey. J Affect Disord 2004, 78(suppl):126-127.
• [17]Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, et al.: Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003, 53(11):1028-1042.
• [18]Barbosa IG, Huguet RB, Mendonca VA, Sousa LP, Neves FS, Bauer ME, Teixeira AL: Increased plasma levels of soluble TNF receptor I in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2011, 261(2):139-143.
• [19]Barbosa IG, Rocha NP, de Miranda AS, Magalhaes PV, Huguet RB, de Souza LP, Kapczinski F, Teixeira AL: Increased levels of adipokines in bipolar disorder. J Psychiatr Res 2012, 46(3):389-393.
• [20]Leonard B, Maes M: Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012, 36(2):764-785.
• [21]Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9(1):46-56.
• [22]Brietzke E, Kapczinski F: TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32(6):1355-1361.
• [23]Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kuhn M, Schuld A, Pollmacher T: Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999, 33(5):407-418.
• [24]Barbosa IG, Rocha NP, Huguet RB, Ferreira RA, Salgado JV, Carvalho LA, Pariante CM, Teixeira AL: Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord 2012, 137(1–3):151-155.
• [25]Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, Yatham LN: Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009, 12(4):447-458.
• [26]Tohen M, Frank E, Bowden CL, Colom F, Ghaemi SN, Yatham LN, Malhi GS, Calabrese JR, Nolen WA, Vieta E, et al.: The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009, 11(5):453-473.